• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管舒缩症状严重程度对健康状况、资源利用和生产力的影响。

Impact of the severity of vasomotor symptoms on health status, resource use, and productivity.

机构信息

Pfizer Inc., New York, NY, USA.

出版信息

Menopause. 2013 May;20(5):518-24. doi: 10.1097/GME.0b013e31827d38a5.

DOI:10.1097/GME.0b013e31827d38a5
PMID:23403500
Abstract

OBJECTIVE

The current study characterizes health-related quality of life, work productivity, and resource use among postmenopausal women by severity of vasomotor symptoms (VMS).

METHODS

Participants were selected from the 2010 US National Health and Wellness Survey. Women aged 40 to 75 years who did not report a history of menstrual bleeding or spotting for 1 year were eligible for analysis (N = 3,267). Cohorts of women with no VMS (n = 1,740), mild VMS (n = 931), moderate VMS (n = 462), and severe VMS (n = 134) were compared after controlling for demographic and health characteristics. Outcome measures were assessed using linear models and included health status, work productivity within the past 7 days, and healthcare resource use within the past 6 months.

RESULTS

The mean age of women experiencing severe VMS was 57.92 years. After demographic and health characteristics had been controlled for, women experiencing severe and moderate VMS reported significantly lower mean health status scores compared with women with no symptoms (P < 0.0001). The mean number of menopause symptom-related physician visits was significantly greater among women with severe, moderate, or mild symptoms than among women with no symptoms (P < 0.0001). Among employed women experiencing VMS, women with severe and moderate symptoms had adjusted presenteeism of 24.28% and 14.3%, versus 4.33% in women with mild symptoms (P < 0.001), and activities of daily living impairment of 31.66% and 17.06%, versus 6.16% in women with mild symptoms (P < 0.0001).

CONCLUSIONS

In postmenopausal women, a greater severity of VMS is significantly associated with lower levels of health status and work productivity, and greater healthcare resource use.

摘要

目的

本研究通过血管舒缩症状(VMS)严重程度对绝经后女性的健康相关生活质量、工作生产力和资源利用进行了描述。

方法

参与者选自 2010 年美国国家健康与健康调查。年龄在 40 至 75 岁之间、且报告过去 1 年无月经出血或点滴出血史的女性有资格进行分析(N=3267)。无 VMS(n=1740)、轻度 VMS(n=931)、中度 VMS(n=462)和重度 VMS(n=134)的女性队列在控制人口统计学和健康特征后进行了比较。使用线性模型评估了健康状况、过去 7 天内的工作生产力和过去 6 个月内的医疗资源使用情况。

结果

经历严重 VMS 的女性的平均年龄为 57.92 岁。在控制了人口统计学和健康特征后,与无症状女性相比,经历严重和中度 VMS 的女性报告的健康状况评分明显较低(P<0.0001)。有严重、中度或轻度症状的女性与无症状女性相比,与绝经症状相关的医生就诊次数明显较多(P<0.0001)。在经历 VMS 的有工作女性中,与轻度症状的女性相比,严重和中度症状的女性调整后的工作出席率分别为 24.28%和 14.3%(P<0.001),日常生活活动受损率分别为 31.66%和 17.06%(P<0.0001)。

结论

在绝经后女性中,VMS 严重程度越高与健康状况和工作生产力降低以及医疗资源利用增加显著相关。

相似文献

1
Impact of the severity of vasomotor symptoms on health status, resource use, and productivity.血管舒缩症状严重程度对健康状况、资源利用和生产力的影响。
Menopause. 2013 May;20(5):518-24. doi: 10.1097/GME.0b013e31827d38a5.
2
A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women.一项针对中年女性血管舒缩症状的流行率、持续时间和对生活质量影响的大型跨国研究。
Menopause. 2011 Jul;18(7):778-85. doi: 10.1097/gme.0b013e318207851d.
3
Oral micronized progesterone for vasomotor symptoms--a placebo-controlled randomized trial in healthy postmenopausal women.口服微粒化黄体酮治疗血管舒缩症状——一项健康绝经后妇女的安慰剂对照随机试验。
Menopause. 2012 Aug;19(8):886-93. doi: 10.1097/gme.0b013e318247f07a.
4
Severity of menopausal symptoms of Jordanian women.约旦女性的更年期症状严重程度。
Climacteric. 2010 Aug;13(4):385-94. doi: 10.3109/13697130903050009.
5
Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States.美国围绝经期和绝经后女性血管舒缩症状的发生频率及严重程度。
Climacteric. 2008 Feb;11(1):32-43. doi: 10.1080/13697130701744696.
6
Incremental direct and indirect costs of untreated vasomotor symptoms.未治疗的血管舒缩症状的增量直接和间接成本。
Menopause. 2015 Mar;22(3):260-6. doi: 10.1097/GME.0000000000000320.
7
Hot flushes and night sweats differ in associations with cardiovascular markers in healthy early postmenopausal women.绝经早期健康女性中,热潮红和盗汗与心血管标志物的相关性不同。
Menopause. 2012 Nov;19(11):1208-14. doi: 10.1097/gme.0b013e31825541cc.
8
Moderate to severe vasomotor symptoms are risk factors for non-alcoholic fatty liver disease in postmenopausal women.绝经后妇女中,中重度血管舒缩症状是发生非酒精性脂肪性肝病的危险因素。
Maturitas. 2018 Nov;117:22-28. doi: 10.1016/j.maturitas.2018.08.011. Epub 2018 Aug 31.
9
Progesterone for hot flush and night sweat treatment--effectiveness for severe vasomotor symptoms and lack of withdrawal rebound.孕激素治疗热潮红和盗汗——对严重血管舒缩症状的疗效和无撤药反弹。
Gynecol Endocrinol. 2012 Oct;28 Suppl 2:7-11. doi: 10.3109/09513590.2012.705390. Epub 2012 Aug 1.
10
A cross-sectional study of equol producer status and self-reported vasomotor symptoms.一项关于雌马酚产生者状态与自我报告的血管舒缩症状的横断面研究。
Menopause. 2015 May;22(5):489-95. doi: 10.1097/GME.0000000000000363.

引用本文的文献

1
Associations of social determinants of health on likelihood of systemic hormone therapy use in midlife women.健康的社会决定因素与中年女性使用全身激素疗法可能性之间的关联。
Biol Sex Differ. 2025 Jun 1;16(1):37. doi: 10.1186/s13293-025-00720-9.
2
Effects of menopause on temperature regulation.更年期对体温调节的影响。
Temperature (Austin). 2025 Apr 23;12(2):92-132. doi: 10.1080/23328940.2025.2484499. eCollection 2025.
3
Prevalence and impact of vasomotor symptoms associated with menopause among Nordic women: Subgroup analysis from an international cross-sectional survey.
北欧女性中与更年期相关的血管舒缩症状的患病率及影响:一项国际横断面调查的亚组分析
Acta Obstet Gynecol Scand. 2025 May 1. doi: 10.1111/aogs.15139.
4
The Burden of Illness of Treatment-Induced Vasomotor Symptoms in Individuals with Breast Cancer: A Systematic Literature Review.乳腺癌患者治疗引起的血管舒缩症状的疾病负担:一项系统文献综述
J Clin Med. 2025 Apr 10;14(8):2601. doi: 10.3390/jcm14082601.
5
An Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects.一项评估非佐匹克隆在健康中国女性受试者中的药代动力学和安全性的开放标签、单剂量和多剂量研究。
Drug Des Devel Ther. 2025 Mar 26;19:2243-2252. doi: 10.2147/DDDT.S486562. eCollection 2025.
6
Clinical Hypnosis and Cognitive Behavioral Therapy for Hot Flashes: A Scoping Review.潮热的临床催眠与认知行为疗法:一项范围综述
Womens Health Rep (New Rochelle). 2025 Jan 8;6(1):1-20. doi: 10.1089/whr.2024.0144. eCollection 2025.
7
Prevalence and impact of vasomotor symptoms due to menopause among women in Canada: A subgroup analysis from an international cross-sectional survey of Women with Vasomotor Symptoms Associated with Menopause (WARM Study).加拿大女性绝经后血管舒缩症状的患病率及影响:一项针对绝经相关血管舒缩症状女性的国际横断面调查(WARM研究)的亚组分析。
Menopause. 2025 Jan 1;32(1):38-44. doi: 10.1097/GME.0000000000002451.
8
Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial.非甾体选择性神经激肽 3(NK3)受体拮抗剂 fezolinetant 治疗不适合激素治疗的绝经相关中重度血管舒缩症状的疗效和安全性:3b 期随机对照试验。
BMJ. 2024 Nov 18;387:e079525. doi: 10.1136/bmj-2024-079525.
9
Treatment satisfaction, unmet needs, and new treatment expectations for vasomotor symptoms due to menopause: women's and physicians' opinions.治疗满意度、未满足需求以及绝经相关血管舒缩症状的新治疗期望:女性和医生的观点。
Menopause. 2024 Sep 1;31(9):769-780. doi: 10.1097/GME.0000000000002399.
10
Exploration of Japanese women seeking acupuncture for menopausal symptoms: a preliminary study.对寻求针灸治疗更年期症状的日本女性的探索:一项初步研究。
Int J Complement Altern Med. 2023;16(6):344-346. doi: 10.15406/ijcam.2023.16.00674. Epub 2023 Dec 18.